SUPN — SUPERNUS PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356576 ·
Last close
$44.63
Market Cap
$2.59B
52W High
$52.96
52W Low
$42.45
ADV30
828,156
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 207,705,000 | 184,314,000 | -5,941,000 | -2,293,000 | 1,500,725,000 | 184,869,000 | 423,920,000 |
| Dec 2025 | 211,572,000 | 188,565,000 | 13,822,000 | -4,105,000 | 1,452,648,000 | 128,448,000 | 390,934,000 |
| Sep 2025 | 192,103,000 | 173,138,000 | -60,231,000 | -45,117,000 | 1,419,754,000 | 151,371,000 | 370,087,000 |
| Jun 2025 | 165,453,000 | 148,626,000 | 12,141,000 | 22,499,000 | 1,382,405,000 | 144,711,000 | 318,505,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$47,331,000
Investing CF
$4,106,000
Financing CF
$9,130,000
CapEx
$-1,338,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.68
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$517,876,000
Inventory
$82,385,000
Receivables
$187,802,000
ST Investments
$180,222,000
EBIT TTM
$-49,030,000
Pretax Income TTM
$-49,030,000
Interest Exp TTM
$0
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$776,833,024
EBITDA
$122,628,000
Free Cash Flow
$132,620,496
Enterprise Value
$2,303,853,568
Total Cash
$384,240,992
Total Debt
$40,903,000
Shares Out
58,039,721
Trailing EPS
$-0.51
Book Value
$18.48
ROE
-2.8%
ROA
1.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 718,952,000 | -36,864,000 | -38,550,000 | 1,452,648,000 | 390,934,000 | — | 47,331,000 |
| Dec 2024 | 661,817,000 | 75,556,000 | 73,865,000 | 1,368,073,000 | 332,340,000 | — | 171,951,000 |
| Dec 2023 | 607,521,000 | 13,403,000 | 1,316,000 | 1,277,673,000 | 356,157,000 | — | 111,085,000 |
| Dec 2022 | 667,238,000 | 45,614,000 | 60,711,000 | 1,702,508,000 | 816,304,000 | — | 116,826,000 |
TTM Snapshot
Revenues TTM
$655,386,000
NetIncome TTM
$45,832,000
OpCashFlow TTM
$0
Assets (Latest)
$1,368,073,000
Forward EPS
$4.34
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $65.00 · spot: $44.63 · call volume: 94 · put volume: 116Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $2.59B | $18.25 | — |
| IMNM | Immunome Inc. | $2.58B | $22.76 | — |
| BHC | Bausch Health Companies Inc. | $2.57B | $6.89 | — |
| ATAI | AtaiBeckley Inc. | $2.66B | $7.18 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.45B | $24.91 | — |
News headlines (Yahoo Finance, 1h cache)
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?
2026-07-28 14:00 · Yahoo
Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?
2026-07-27 16:10 · Yahoo
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
2026-07-14 12:30 · Yahoo
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
2026-07-09 13:25 · Yahoo
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
2026-06-23 15:52 · Yahoo
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
2026-07-30 14:00 · Yahoo
Is Rising Earnings Optimism Altering The Investment Case For Supernus Pharmaceuticals (SUPN)?
2026-07-28 09:12 · Yahoo
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
2026-07-24 14:57 · Yahoo
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
2026-07-22 21:05 · Yahoo
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
2026-07-16 09:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.